Skip to main content
Premium Trial:

Request an Annual Quote

Epigenomics' 2008 Revenues Flat Year over Year; Net Loss Declines

NEW YORK (GenomeWeb News) – German molecular diagnostics firm Epigenomics today reported fiscal-year 2008 revenues of €2.6 million (US$3.4 million), flat with revenues of €2.6 million for 2007.

The company's FY 2008 net loss dropped 7 percent to €12.3 million, or €.47 per share, from €13.2 million, or €.74 per share.

The firm noted that its R&D costs declined 5 percent to €10 million from €10.5 million year over year.

Epigenomics said that it and Abbott are in the final stages of development and clinical validation of the firm's mSEPT9 assay for colorectal cancer. The test is on track for a fourth-quarter 2009 launch in Europe followed by the filing for US approval that is planned for 2010, said Epigenomics.

The Berlin-based firm also has a partnership with clinical lab giant Quest Diagnostics to develop and launch a laboratory-developed test version of the mSEPT9 assay.

Epigenomics finished the year with €12.1 million in liquid assets.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.